TAF7 Antibody

What is TAF7 and what are its key functions in transcription?

TAF7 (Transcription initiation factor TFIID subunit 7, also known as TAFII55) is a component of the TFIID basal transcription factor complex that plays a critical role in RNA polymerase II (Pol II)-dependent transcription. TAF7 functions as part of a promoter DNA binding subcomplex of TFIID, together with TAF1 and TAF2 .

Research has revealed that TAF7 has multiple functions:

• As a component of TFIID, it contributes to preinitiation complex (PIC) assembly

• It regulates TAF1 activity during transcription initiation

• It inhibits the kinase activities of both TFIIH and P-TEFb, affecting phosphorylation of RNA polymerase II CTD

• It exists in both nuclear and cytoplasmic compartments, with distinct roles in each

The requirement for TAF7 varies among different cell types, with proliferating cells generally showing a greater dependency than quiescent, differentiated cells .

What are the functional domains and structural characteristics of TAF7?

TAF7 contains several key functional domains that are critical for its diverse activities:

The TAF1-TAF7 interaction involves a large, predominantly hydrophobic heterodimer interface with extensive cofolding of TAF subunits. This structure suggests that TAF1 is likely only stable in the presence of a suitable binding partner like TAF7 .

What applications are TAF7 antibodies commonly used for in research?

TAF7 antibodies are versatile tools for investigating both the expression and function of TAF7 in various research contexts:

Different TAF7 antibodies may recognize distinct epitopes, such as amino acids 100-250 , which can affect their suitability for specific applications. The optimal dilution should always be determined experimentally for each antibody and application .

How can researchers effectively study TAF7's dual nuclear and cytoplasmic functions?

TAF7 exhibits distinct functions in the nucleus and cytoplasm, requiring sophisticated experimental approaches to dissect these roles:

For nuclear function studies:

• Use ChIP assays to examine TAF7 association with specific promoters and coding regions

• Implement TAF7 knockdown followed by RNA-seq to identify transcriptional targets

• Use proximity ligation assays to detect interactions with nuclear partners (TBP, TAF1)

• Design TAF7 mutants lacking nuclear export signals (NES) to examine nuclear-restricted function

For cytoplasmic function studies:

• Employ subcellular fractionation to isolate cytoplasmic TAF7 complexes

  • As demonstrated in multiple studies, TAF7 can be detected in cytoplasmic fractions at remarkable concentrations relative to nuclear TAF7

• Perform polysome profiling to examine TAF7 association with ribosomes

  • TAF7 has been shown to cosediment with RPL5 in both polysome and monosome fractions

• Use RIP assays to identify RNA targets of cytoplasmic TAF7

  • Research has demonstrated that TAF7 coimmunoprecipitates a spectrum of RNA species

• Express TAF7 mutants lacking RNA binding domain (RBD) to examine translation functions

  • Mutation of amino acids between 140-155 (TAF7 RBD) abrogates binding to RNA

For examining its shuttle between compartments, researchers should consider:

• Using TAF7 (∆NES) mutants that localize predominantly to the nucleus

• Employing fluorescence recovery after photobleaching (FRAP) to measure nucleocytoplasmic trafficking kinetics

What are the optimal protocols for studying TAF7's interaction with chromatin and RNA?

For chromatin interaction studies (ChIP protocol):

• Crosslinking: Fix cells with 1% formaldehyde for 10 minutes at room temperature

• Chromatin preparation: Sonicate to obtain 200-500bp fragments

• Immunoprecipitation:

  • Use 2-5μg of TAF7 antibody per IP reaction

  • Include IgG control and input samples

  • Incubate overnight at 4°C

• Washing: Use increasingly stringent buffers to reduce background

• Analysis:

  • qPCR for known targets

  • ChIP-seq for genome-wide binding profiles

Published research has demonstrated that TAF7 is associated with initiation/elongation complexes in situ in tissues and colocalizes with P-TEFb and Pol II downstream of the promoter .

For RNA interaction studies (RIP protocol):

• Cell lysis: Use non-denaturing conditions to preserve protein-RNA interactions

• Immunoprecipitation:

  • Use 5μg of TAF7 antibody

  • Include control IgG immunoprecipitation

• RNA extraction: TRIzol method followed by DNase treatment

• Analysis options:

  • RT-qPCR for known target RNAs

  • 3′ end-labeling and RNA gel analysis

  • RNA-seq for comprehensive identification of bound RNAs

Research has shown that anti-TAF7 antibodies, but not control mouse IgG, coimmunoprecipitate a spectrum of RNA species from cells .

How can TAF7 antibodies be effectively used to investigate its role in cancer progression?

TAF7 has been identified as a promoter of triple-negative breast cancer (TNBC) metastasis, making it an important target for cancer research . Researchers can effectively investigate its role using TAF7 antibodies through:

Expression analysis in clinical samples:

Functional studies in cancer cell lines:

• Western blotting to quantify TAF7 expression across cancer cell lines

  • RT-qPCR and western blotting analyses have revealed that the expression level of TAF7 in TNBC cells was significantly higher than in normal breast cell lines

• Immunofluorescence to examine subcellular localization in cancer vs. normal cells

• ChIP-seq to identify cancer-specific TAF7 genomic binding sites

  • TAF7 has been shown to directly bind to the SAA1 promoter in TNBC cells

Mechanistic investigations:

• Combine TAF7 knockdown with migration/invasion assays

  • Research has demonstrated that knockdown of TAF7 significantly inhibited the migration and invasion of MDA-MB-231 and MDA231-LM2 cells

• Co-immunoprecipitation to identify cancer-relevant interaction partners

• RNA immunoprecipitation to identify cancer-specific RNA targets

Animal models:

• Use TAF7 antibodies for IHC analysis of xenograft tumors and metastases

  • In vivo experiments have shown that inhibition of TAF7 attenuated the formation of lung metastases, as confirmed by H&E staining of lung tissue

What controls should be included when using TAF7 antibodies for various applications?

For Western Blotting:

• Positive control: Cell line with known TAF7 expression (HeLa, 293T)

• Negative control: TAF7 knockdown/knockout cells

• Loading control: Housekeeping protein (β-actin, GAPDH)

• Molecular weight validation: TAF7 should appear at 55 kDa

• Blocking peptide: Pre-incubation of antibody with immunizing peptide should abolish signal

For Immunoprecipitation:

• Input sample: 5-10% of pre-IP lysate

• IgG control: Non-specific antibody of same isotype

• Reciprocal IP: When studying interactions, perform IP with antibodies to both proteins

• Beads-only control: To detect non-specific binding to beads

For Immunofluorescence/IHC:

• Isotype control: Non-specific antibody of same isotype

• Peptide competition: Pre-incubation with immunizing peptide

• TAF7 knockdown cells: To verify specificity

• Secondary antibody-only control: To assess background

For ChIP experiments:

• Input chromatin: 5-10% of pre-IP sample

• IgG control: Non-specific antibody of same isotype

• Positive genomic region: Known TAF7 binding site

• Negative genomic region: Region known not to bind TAF7

Why might TAF7 antibodies show different subcellular localization patterns and how should this be interpreted?

TAF7 antibodies may show different subcellular localization patterns due to several factors:

Biological reasons:

• Genuine dual localization: TAF7 has both nuclear and cytoplasmic functions

  • Studies have demonstrated substantial levels of TAF7 in the cytoplasm of HeLa cells by immunofluorescence with anti-TAF7 antibodies

  • Cellular fractionation of both HeLa and mouse B lymphoma cells further demonstrated the presence of cytoplasmic TAF7

• Dynamic shuttling: TAF7 contains both nuclear localization signals and nuclear export signals (NES)

  • The TAF7 (ΔNES) mutant localizes predominantly to the nucleus, confirming that cytoplasmic localization results from export of nuclear TAF7

• Cell cycle dependence: TAF7 phosphorylation and localization can change during cell cycle

  • During G1 phase, TAF7 is phosphorylated at serine 264, affecting its association with TFIID

• Cell type differences: Expression and localization can vary between cell types

  • The requirement for TAF7 is generally greater in proliferating cells than in quiescent, differentiated cells

Technical considerations:

• Epitope accessibility: Different antibodies recognize different epitopes that may be masked in certain compartments or protein complexes

• Fixation effects: Different fixation methods can affect epitope recognition and apparent localization

• Specificity issues: Some antibodies may cross-react with related proteins

Interpretation guidelines:

• Use multiple antibodies recognizing different epitopes

• Combine immunofluorescence with subcellular fractionation and western blotting

• Include appropriate controls (described in 3.1)

• Validate with genetic approaches (TAF7 knockdown/knockout, mutant expression)

What are the common issues in TAF7 immunoprecipitation experiments and how can they be resolved?

Common Issue 1: Low IP efficiency

• Potential causes: Low antibody affinity, insufficient antibody amount, epitope masking in complexes

• Solutions:

  • Try different antibodies recognizing distinct TAF7 epitopes

  • Increase antibody amount (up to 5μg per IP)

  • Optimize lysis conditions (try different detergents: CHAPS, Triton X-100, NP-40)

  • Extend incubation time (overnight at 4°C)

Common Issue 2: High background

• Potential causes: Non-specific binding, insufficient washing, cross-reactivity

• Solutions:

  • Include blocking proteins (BSA, non-fat milk) in IP buffer

  • Increase stringency and number of washes

  • Pre-clear lysates with protein A/G beads

  • Use highly cross-adsorbed secondary antibodies

  • For western blot detection, use HRP-conjugated protein A/G to avoid detection of IP antibody

Common Issue 3: Failure to detect TAF7 interaction partners

• Potential causes: Harsh lysis conditions disrupting interactions, transient interactions

• Solutions:

  • Use milder lysis buffers (avoid ionic detergents like SDS)

  • Consider crosslinking before lysis (formaldehyde or DSP)

  • For RNA-protein interactions, use UV crosslinking

  • For known interactors like TAF1, optimize conditions based on published studies showing TAF1-TAF7 has a large hydrophobic heterodimer interface

Common Issue 4: Inconsistent results with nuclear TAF7

• Potential causes: Incomplete nuclear extraction, degradation

• Solutions:

  • Use nuclear extraction protocols with high salt (>300mM NaCl)

  • Include phosphatase inhibitors (TAF7 phosphorylation affects interactions)

  • Add protease inhibitors to prevent degradation

  • Consider analyzing nuclear and cytoplasmic fractions separately

How does TAF7 function as a cytoplasmic regulator of translation?

Recent research has revealed an unexpected role for TAF7 in the cytoplasm as a regulator of translation :

Key findings:

• Cytoplasmic localization: Substantial levels of TAF7 are present in the cytoplasm

  • TAF7 contains a nuclear export signal (NES) between amino acids 203-243 that mediates its export from the nucleus

• Association with translation machinery:

  • TAF7 cosediments with RPL5 in both polysome and monosome fractions

  • Cytoplasmic TAF7 elutes at a position equivalent to 440 kDa, indicating association with a multiprotein complex distinct from TFIID

  • TAF7 associates with ribosomal proteins (RPL5, RPL8) as demonstrated by co-immunoprecipitation

• RNA binding activity:

  • TAF7 contains an RNA binding domain (RBD) mapped to amino acids 140-155

  • Anti-TAF7 antibodies coimmunoprecipitate a spectrum of RNA species from cells

  • This RNA binding site is highly homologous to that of HIV-1 Tat

• Functional impact on protein synthesis:

  • Cells expressing TAF7 with mutations in the RNA binding domain show significantly decreased puromycin incorporation, indicating reduced total protein synthesis

  • TAF7 appears to be an RNA chaperone that contributes to the regulation of protein synthesis

• Transcript delivery model:

  • TAF7 appears to link transcription and translation by delivering its transcripts to polysomes for translation

  • This provides a mechanism for coupling these two fundamental gene expression processes

What is known about TAF7's role in cancer metastasis?

Recent research has identified TAF7 as a significant promoter of cancer metastasis, particularly in triple-negative breast cancer (TNBC) :

Key findings and mechanisms:

What recent insights have been gained about TAF7-TAF1 structural interaction?

Recent structural studies have provided critical insights into the TAF1-TAF7 interaction, challenging previous models and revealing new functional aspects :

Key structural findings:

• Complex architecture:

  • The TAF1-TAF7 complex displays novel architecture characterized by a large predominantly hydrophobic heterodimer interface

  • Extensive cofolding of TAF subunits is observed within the complex

• Interaction stability:

  • The TAF1-TAF7 interaction involves deeply intertwined β-strands from each protein contributing to a common β-barrel structure

  • This interface would likely form only concomitantly with folding during protein synthesis, suggesting co-translational assembly

• Functional implications:

  • The structure suggests that TAF1 is only likely to be stable in the presence of a suitable binding partner like TAF7

  • TAF7 dissociation would likely disrupt TAF1 folding and functional viability

  • This challenges the previously proposed model that TAF7 acts simply as a dissociable inhibitor of TAF1

• Histone mark binding:

  • TAF1-TAF7 complex contains two prominent conserved surface pockets

  • One pocket binds selectively to the inhibitory trimethylated histone H3 mark on Lys27 (H3K27me3)

  • This binding is regulated by phosphorylation at neighboring sites

• Hierarchical assembly model:

  • Research using co-localization studies has shown that ~40% of TAF1 mRNAs co-localize with TAF7 spots, suggesting co-translational assembly

  • About 50% of TBP-positive TAF1 RNA spots were simultaneously co-localized with TAF7, indicating a coordinated assembly process

  • Puromycin treatment drastically reduces the frequency of co-localization, confirming the co-translational nature of these interactions

How does TAF7 regulate the transition from transcription initiation to elongation?

TAF7 plays a critical role in regulating the transition from transcription initiation to elongation through multiple mechanisms :

Regulatory mechanisms:

• Interaction with transcription factors:

  • TAF7 physically interacts with both the general transcription factor TFIIH and the elongation factor P-TEFb

  • These interactions have been demonstrated through in vitro pull-down assays and co-immunoprecipitation experiments

• Inhibition of kinase activities:

  • TAF7 inhibits the CDK7 kinase activity of TFIIH, preventing phosphorylation of RNA Pol II CTD Ser-5

  • TAF7 binding to P-TEFb inhibits its CDK9-mediated phosphorylation of Pol II CTD Ser-2

  • These inhibitory activities were demonstrated through in vitro kinase assays

• Post-PIC assembly function:

  • In vitro transcription reactions show that TAF7 inhibits steps after PIC assembly and formation of the first phosphodiester bonds

  • This suggests TAF7 regulates the transition from initiation to elongation

• Co-elongation with transcription machinery:

  • In vivo ChIP analyses demonstrate that TAF7 co-elongates with P-TEFb and Pol II downstream of the promoter

  • The relative abundance of TAF7 parallels that of cyclin T1 through gene bodies

• Proposed checkpoint model:

  • TAF7 inhibits TAF1 AT activity until PIC assembly is complete, preventing premature initiation

  • Upon completion of PIC assembly, TAF7 is released from TAF1, allowing transcription to initiate

  • TAF7 inhibition of TFIIH phosphorylation delays 5′ cap formation until formation of the first phosphodiester bonds

  • This effectively creates a pause in initiation, consistent with the known pausing of Pol II ≈20–60 bp downstream of the transcription start site

  • For genes whose expression is dynamically regulated by extrinsic signaling events, this pausing could provide a mechanism to regulate transcription rate

What are promising areas for future research on TAF7 function?

Based on recent discoveries, several promising research directions for TAF7 are emerging:

• Detailed mapping of TAF7's RNA interactome:

  • Comprehensive identification of RNAs bound by TAF7 in different cellular compartments

  • Investigation of sequence or structural motifs recognized by TAF7's RNA binding domain

  • Examination of how RNA binding affects TAF7's interactions with other proteins

• TAF7's role in coordinating transcription and translation:

  • Mechanistic studies of how TAF7 delivers transcripts to polysomes

  • Investigation of whether TAF7 preferentially affects translation of specific mRNA subsets

  • Examination of TAF7's potential role in stress granule or P-body formation

• TAF7 as a cancer therapeutic target:

  • Development of small molecule inhibitors targeting TAF7-SAA1 interaction

  • Investigation of TAF7 as a biomarker for metastatic potential in different cancer types

  • Exploration of synthetic lethal interactions with TAF7 in cancer cells

• Structural studies of full-length TAF7 complexes:

  • Cryo-EM studies of TAF7 within the complete TFIID complex

  • Structural analysis of the 440 kDa cytoplasmic TAF7 complex

  • Investigation of how post-translational modifications affect TAF7 structure and function

• Role in chromatin regulation:

  • Further characterization of TAF7-TAF1 binding to H3K27me3 and other histone marks

  • Investigation of TAF7's potential role in bridging repressive chromatin states with active transcription

  • Genome-wide mapping of TAF7 binding sites relative to chromatin states

What emerging technologies might advance TAF7 research?

Several cutting-edge technologies show promise for advancing TAF7 research:

• Proximity labeling techniques:

  • BioID or TurboID fused to TAF7 to identify its protein interaction network in living cells

  • APEX-based approaches to map TAF7's protein neighborhood with subcellular resolution

  • RNA-protein interaction mapping using TRIBE or APEX-seq

• Live-cell imaging approaches:

  • Single-molecule tracking of TAF7 to monitor its dynamics between nuclear and cytoplasmic compartments

  • Visualization of TAF7-RNA interactions using MS2/PP7 systems

  • FRAP or photoactivatable fluorophores to measure TAF7 mobility in different compartments

• High-resolution structural methods:

  • Cryo-electron tomography to visualize TAF7 within native cellular contexts

  • Integrative structural biology combining X-ray crystallography, NMR, and computational modeling

  • Hydrogen-deuterium exchange mass spectrometry to map dynamic protein interfaces

• CRISPR-based functional screening:

  • CRISPRi/CRISPRa screens to identify genetic interactions with TAF7

  • Base editing or prime editing to introduce specific TAF7 mutations

  • CRISPR-mediated tagging of endogenous TAF7 for live-cell studies

• Single-cell multi-omics:

  • Single-cell RNA-seq combined with protein measurements to correlate TAF7 levels with transcriptome changes

  • Spatial transcriptomics to examine TAF7 function in tissue contexts

  • Combinatorial indexing approaches to map TAF7 chromatin interactions in thousands of single cells